News Related to Pneumococcal Vaccine (20-Valent)

Related coverage linked through entity extraction aliases.

Pfizer reports positive Phase II data for 25-valent pneumococcal vaccine in infants

May 21, 2026

Pfizer reported positive Phase II data for PF-07872412, a 25-valent pneumococcal conjugate vaccine candidate in infants. Serotype 3 geometric mean titers were 8.8-fold higher after dose three and about 15-fold higher after dose four versus PREVNAR 20.

Vaxcyte Launches VAX-31 Phase 3 Program, Targets Adult BLA Filing by End of 2027

Feb 15, 2026

Vaxcyte has initiated its Phase 3 adult program for VAX-31, a 31-valent pneumococcal conjugate vaccine, with the pivotal OPUS-1 trial enrolling 4,000 adults aged 50 and older. The company plans to submit a Biologics License Application by the end of next year.